In early June, an advisory committee to the FDA voted against the effectiveness on MDMA as a treatment for post-traumatic stress disorder. Drs. Frederick Barrett and Alan Davis comment on the lessons that can be learned from the committee’s stance, viewing it as a learning experience for ongoing studies to follow “the most rigorous methods”.

Dr. David Yaden offers his perspective on the “real risks and benefits of psychedelics” after the FDA’s rejection of MDMA for the treatment of PTSD. He hopes that public sentiment will become more “balanced and nuanced” regarding the state of evidence on psychedelics as medicine.

Oprah Daily describes the history of hallucinogenic medicines and personal accounts on existing research from universities and centers including the CPCR. Dr. Frederick Barrett discusses the “entropic effect” of psychedelics as well as the realistic risks and care that should be taken when handling the future of psychedelic research.